These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 21954897)

  • 21. Molecular genetics of exercise-induced polymorphic ventricular tachycardia: identification of three novel cardiac ryanodine receptor mutations and two common calsequestrin 2 amino-acid polymorphisms.
    Laitinen PJ; Swan H; Kontula K
    Eur J Hum Genet; 2003 Nov; 11(11):888-91. PubMed ID: 14571276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child.
    Duan H; Lu Y; Yan S; Qiao L; Hua Y; Li Y; Zhou K; Wang C
    Medicine (Baltimore); 2018 Apr; 97(16):e0368. PubMed ID: 29668588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Associated With Ryanodine Receptor (RyR2) Gene Mutations　- Long-Term Prognosis After Initiation of Medical Treatment.
    Kawata H; Ohno S; Aiba T; Sakaguchi H; Miyazaki A; Sumitomo N; Kamakura T; Nakajima I; Inoue YY; Miyamoto K; Okamura H; Noda T; Kusano K; Kamakura S; Miyamoto Y; Shiraishi I; Horie M; Shimizu W
    Circ J; 2016 Aug; 80(9):1907-15. PubMed ID: 27452199
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Catecholaminergic polymorphic ventricular tachycardia in a child: a case report.
    Garabedian L; Verryckt A; Panzer J; De Wolf D
    Acta Paediatr; 2008 Jan; 97(1):127-9. PubMed ID: 18052993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential Diagnosis Between Catecholaminergic Polymorphic Ventricular Tachycardia and Long QT Syndrome Type 1　- Modified Schwartz Score.
    Ozawa J; Ohno S; Fujii Y; Makiyama T; Suzuki H; Saitoh A; Horie M
    Circ J; 2018 Aug; 82(9):2269-2276. PubMed ID: 29925740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel RYR2 loss-of-function mutation (I4855M) is associated with left ventricular non-compaction and atypical catecholaminergic polymorphic ventricular tachycardia.
    Roston TM; Guo W; Krahn AD; Wang R; Van Petegem F; Sanatani S; Chen SR; Lehman A
    J Electrocardiol; 2017; 50(2):227-233. PubMed ID: 27646203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic characterization of familial CPVT after 30 years.
    Beery TA; Shah MJ; Benson DW
    Biol Res Nurs; 2009 Jul; 11(1):66-72. PubMed ID: 19398417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calsequestrin 2 (CASQ2) mutations increase expression of calreticulin and ryanodine receptors, causing catecholaminergic polymorphic ventricular tachycardia.
    Song L; Alcalai R; Arad M; Wolf CM; Toka O; Conner DA; Berul CI; Eldar M; Seidman CE; Seidman JG
    J Clin Invest; 2007 Jul; 117(7):1814-23. PubMed ID: 17607358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct U wave changes in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT).
    Aizawa Y; Komura S; Okada S; Chinushi M; Aizawa Y; Morita H; Ohe T
    Int Heart J; 2006 May; 47(3):381-9. PubMed ID: 16823244
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Pflaumer A; Davis AM
    Heart Lung Circ; 2012 Feb; 21(2):96-100. PubMed ID: 22119737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New exome data question the pathogenicity of genetic variants previously associated with catecholaminergic polymorphic ventricular tachycardia.
    Jabbari J; Jabbari R; Nielsen MW; Holst AG; Nielsen JB; Haunsø S; Tfelt-Hansen J; Svendsen JH; Olesen MS
    Circ Cardiovasc Genet; 2013 Oct; 6(5):481-9. PubMed ID: 24025405
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene.
    Nof E; Belhassen B; Arad M; Bhuiyan ZA; Antzelevitch C; Rosso R; Fogelman R; Luria D; El-Ani D; Mannens MM; Viskin S; Eldar M; Wilde AA; Glikson M
    Heart Rhythm; 2011 Oct; 8(10):1546-52. PubMed ID: 21699856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. S4153R is a gain-of-function mutation in the cardiac Ca(2+) release channel ryanodine receptor associated with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation.
    Zhabyeyev P; Hiess F; Wang R; Liu Y; Wayne Chen SR; Oudit GY
    Can J Cardiol; 2013 Aug; 29(8):993-6. PubMed ID: 23498838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Catecholaminergic polymorphic ventricular tachycardia from bedside to bench and beyond.
    Katz G; Arad M; Eldar M
    Curr Probl Cardiol; 2009 Jan; 34(1):9-43. PubMed ID: 19068246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ryanodine receptor mutations presenting as idiopathic ventricular fibrillation: a report on two novel familial compound mutations, c.6224T>C and c.13781A>G, with the clinical presentation of idiopathic ventricular fibrillation.
    Paech C; Gebauer RA; Karstedt J; Marschall C; Bollmann A; Husser D
    Pediatr Cardiol; 2014 Dec; 35(8):1437-41. PubMed ID: 24950728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Catecholaminergic polymorphic ventricular tachycardia (CPVT) initially diagnosed as idiopathic ventricular fibrillation: the importance of thorough diagnostic work-up and follow-up.
    Siegers CE; Visser M; Loh P; van der Heijden JF; Hassink RJ
    Int J Cardiol; 2014 Dec; 177(2):e81-3. PubMed ID: 25456695
    [No Abstract]   [Full Text] [Related]  

  • 37. Non-ventricular, Clinical, and Functional Features of the RyR2(R420Q) Mutation Causing Catecholaminergic Polymorphic Ventricular Tachycardia.
    Domingo D; Neco P; Fernández-Pons E; Zissimopoulos S; Molina P; Olagüe J; Suárez-Mier MP; Lai FA; Gómez AM; Zorio E
    Rev Esp Cardiol (Engl Ed); 2015 May; 68(5):398-407. PubMed ID: 25440180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Catecholaminergic polymorphic ventricular tachycardia.
    Liu N; Colombi B; Raytcheva-Buono EV; Bloise R; Priori SG
    Herz; 2007 May; 32(3):212-7. PubMed ID: 17497254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells.
    Itzhaki I; Maizels L; Huber I; Gepstein A; Arbel G; Caspi O; Miller L; Belhassen B; Nof E; Glikson M; Gepstein L
    J Am Coll Cardiol; 2012 Sep; 60(11):990-1000. PubMed ID: 22749309
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Postmortem molecular analysis for fatal arrhythmogenic disease in sudden unexplained death.
    Nishio H; Suzuki K
    Leg Med (Tokyo); 2009 Apr; 11 Suppl 1():S119-20. PubMed ID: 19261510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.